CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 45 enrolled / 45 target
Drug / intervention
CP-945,598 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01517100
NCT01517100Phase 1CompletedUpdate Overdue (0.3/mo)Completion was 140mo ago

The Roles of Endocannabinoids in Insulin Secretion and Action

National Institute on Aging (NIA)·interventional·Posted Jan 25, 2012·Updated Jun 18, 2026

In Brief

A Phase 1 clinical trial evaluating Nabilone, CP-945,598, and 2 other interventions for Healthy Volunteers. Completed, enrolled 45 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

Background: \- The endocannabinoid system is involved in different body functions and processes. It helps regulate appetite and mood, and sends signals to the nervous system. It may also be involved in how the body produces insulin during digestion. Researchers want to test two drugs that work on the endocannabinoid system: nabilone and CP-945,598. These drugs may be able to affect insulin levels in the blood. This information may suggest possible new treatments for people with diabetes. Objectives: \- To study how the endocannabinoid system is involved in insulin production and action. Eligibility: \- Healthy men between 21 and 55 years of age. Design: * Participants will be screened with a physical exam and medical history. They will provide blood and urine samples. They will also have imaging studies to test their brain responses, especially to food-related cues. Some participants will also have a study visit to test their insulin resistance levels. * Participants will have four separate study visits 6 weeks apart. They will keep a food diary before each visit. At each visit, they will have one of the following combinations of drugs: * Double placebo * Placebo and nabilone * Placebo and low dose of CP-945,598 * Placebo and high dose of CP-945,598. * Participants will have follow-up visits 1 week after each study visit. Blood samples will be taken.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 25, 2012
Enrollment StartJan 5, 2012
Primary CompletionOct 6, 2014
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.4 years ago

Interventions

Nabiloneother

CB agonist

CP-945,598drug

Cannabinoid Receptor 1 antagonist

hyperglycemic clampother

assesses beta cell response

euglycemic-hyperinsulinemic clampother

measures insulin sensitivity

Nabiloneother

cannabinoid receptor agonist